{"nctId":"NCT02684851","briefTitle":"The Use of Tranexamic Acid to Reduce Blood Loss in Acetabular Surgery","startDateStruct":{"date":"2012-10"},"conditions":["Acetabular Fractures"],"count":87,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"Tranexamic","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Tranexamic Acid"]}],"interventions":[{"name":"Tranexamic Acid","otherNames":["Tranexamic acid (anti-fibrinolytic agents )"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* All patients aged 18 or above undergoing acetabular ORIF.\n\nExclusion Criteria:\n\n* All patients aged below 18 years undergoing acetabulum surgery\n* Patients with color-blindness (color vision changes used to assess toxicity)\n* Patients with subarachnoid hemorrhage.\n* Patients with active intravascular coagulation.\n* Patients with a previous history of venous thromboembolism or with a history of hypercoaguable conditions (i.e. Factor V Leiden, antiphospholipid antibody).\n* Prisoners\n* Pregnant women","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Allogenic Blood Transfusion Rates","description":"Number of participant received allogenic blood transfusions.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]},{"type":"PRIMARY","title":"Units of Packed Red Blood Cells Transfused","description":"Average units packed red blood cells transfused among participants","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.65","spread":"1.27"},{"groupId":"OG001","value":"2.36","spread":"0.81"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a Thromboembolic Event","description":"Do patients undergoing acetabular ORIF who receive tranexamic acid have a higher risk for thromboembolic events than patients who receive placebo?","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Estimate Blood Loss","description":"To measure average estimate perioperative blood loss","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"727.6","spread":"702.52"},{"groupId":"OG001","value":"560.1","spread":"378.4"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":45},"commonTop":[]}}}